IMMODULON

• 72190 - Other research and experimental development on natural sciences and engineering
• 86900 - Other human health activities

Immodulon is a private, late-stage clinical company developing IMM-101, a novel broad spectrum immuno modulator. IMM-101 induces a broad immune response, modulating the innate and adaptive immune systems with a potential to complement existing therapies, including targeted immunotherapies and cytotoxics. IMM-101 has the potential to work in difficult-to-treat tumours, including those that have been considered immunologically ‘cold'.

Also known as: Immodulon Therapeutics, IMMODULON THERAPEUTICS LIMITED, Immodulon Therapeutics Ltd

Registration numbers: 06223291 (CH)

Primary location: LONDON